Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
Peptides like BPC-157, TB-500, and GHK-Cu have shown tissue-repair effects in animal studies — supporting angiogenesis, collagen, and wound closure — but human evidence is limited, none are FDA-approved for healing, and U.S. compounding access is under review. Consult a healthcare provider.
Peptides for wound healing — most notably BPC-157, TB-500 (thymosin beta-4), and GHK-Cu — have been studied in animal models for tissue repair, where they appear to support angiogenesis, collagen organization, and faster wound closure. Human clinical evidence remains limited, none are FDA-approved for healing, and U.S. compounding access is under active review.
Wound-healing peptides at a glance
- What they are: short synthetic or naturally occurring peptides studied for tissue repair (research peptides, not approved drugs)
- Most-discussed: BPC-157, TB-500 / thymosin beta-4 (Tβ4), GHK-Cu (copper tripeptide)
- Studied mechanisms (mostly preclinical): angiogenesis, fibroblast and keratinocyte migration, collagen synthesis and organization, reduced inflammation
- Commonly cited research dosing: BPC-157 ~250–500 mcg/day; TB-500 ~2–2.5 mg ~2x/week; GHK-Cu often topical or ~1–2 mg (research protocols vary widely)
- Evidence level: strong preclinical (animal), limited human; no randomized controlled trials confirming healing benefit in humans
- FDA status (June 2026): none approved for wound healing; removed from the 503A interim Category 2 list in April 2026; Pharmacy Compounding Advisory Committee review scheduled July 23–24, 2026
- Best-studied uses (animal models): tendon/ligament and muscle repair (BPC-157, TB-500); skin and dermal wounds (GHK-Cu, TB-500)
What are wound-healing peptides?
Wound-healing peptides are short chains of amino acids studied for their effects on the biological processes that repair tissue: inflammation control, new blood-vessel formation (angiogenesis), cell migration, and the synthesis and remodeling of collagen and other extracellular-matrix proteins.
The three most discussed in this category are distinct molecules. BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence in human gastric juice. TB-500 is a synthetic fragment related to thymosin beta-4 (Tβ4), a naturally occurring actin-binding protein that the body upregulates at sites of injury. GHK-Cu is a copper-bound tripeptide (glycyl-L-histidyl-L-lysine) found naturally in human plasma, with levels that decline with age.
None of these is an FDA-approved drug for wound healing. They are sold as "research chemicals," and the human evidence base is far thinner than the marketing around them suggests. This guide summarizes what peer-reviewed research actually reports — and where the gaps are.
How might peptides support wound and surgical recovery?
In preclinical research, these peptides appear to act on overlapping but distinct repair pathways.
BPC-157 has been studied primarily in rodent models of tendon, ligament, and muscle injury. In a rat Achilles tendon-to-bone model, BPC-157 was associated with improved functional recovery, greater biomechanical strength (load to failure and stiffness), better collagen-fiber organization, and increased vascularization compared with controls (Krivic et al., 2006, J Orthop Res). Mechanistic work suggests BPC-157 upregulates growth-hormone-receptor expression in tendon fibroblasts (Chang et al., 2014, Molecules), and other rodent studies describe effects on the nitric-oxide pathway and angiogenesis.
Thymosin beta-4 / TB-500 is one of the better-characterized repair peptides in animal dermal models. In a foundational rat study, Tβ4 applied topically or systemically increased re-epithelialization by 42% at day 4 and by as much as 61% at day 7 versus saline controls, with increased collagen deposition and angiogenesis; in vitro, Tβ4 stimulated keratinocyte migration in the picogram range (Malinda et al., 1999, J Invest Dermatol).
GHK-Cu has been studied for skin and dermal repair. Reviews report that GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis, attracts immune and endothelial cells to injury sites, and accelerated wound healing and blood-vessel formation in animal models, while acting as an antioxidant by binding copper ions (Pickart et al., 2015, Biomed Res Int).
Research in animal models suggests these peptides may support tissue repair; they do not "heal" or "cure" injuries, and these mechanisms have not been confirmed to translate to clinical wound or surgical outcomes in humans. Consult your healthcare provider before starting any peptide protocol.
What does the human evidence actually show?
This is the most important section to read honestly. The preclinical signal is genuinely interesting; the human evidence is weak.
For BPC-157, there are currently no completed randomized controlled trials demonstrating a wound-healing or tissue-repair benefit in humans. A 2025 systematic review of BPC-157 in orthopedic and sports-medicine applications identified roughly 35 preclinical studies but only a single clinical study, underscoring how little controlled human data exists [VERIFY: exact study counts — Vasireddi et al., 2025, HSS Journal / Orthop J Sports Med]. The most-cited "human" data are small, uncontrolled, retrospective case series, some authored by clinicians with commercial ties to selling the peptide.
For TB-500 / thymosin beta-4, Tβ4 itself has been evaluated in human clinical trials for conditions such as chronic dermal wounds and ophthalmic surface injury, with mixed and not definitively positive results [VERIFY: specific Tβ4 trial outcomes and ClinicalTrials.gov identifiers]. TB-500 (the fragment sold as a research peptide) is not the same regulated product used in those trials.
For GHK-Cu, the strongest human data are in cosmetic dermatology — topical creams improving skin density, firmness, and the appearance of fine lines over ~12 weeks — rather than in surgical-wound or deep-tissue recovery (Pickart et al., 2015, Biomed Res Int).
Bottom line: "studied in animal models" is not the same as "proven in people." Discuss expectations realistically with a healthcare provider.
What dosing do research protocols commonly cite?
The figures below describe parameters reported in published research and clinic protocols. They are not a recommendation, and they should never be self-administered. Routes, doses, and cycle lengths in the research literature vary widely and were studied under controlled conditions.
| Peptide | Commonly cited research dose | Frequency | Typical cycle | Route in research |
|---|---|---|---|---|
| BPC-157 | ~250–500 mcg | once or twice daily | ~4–8 weeks | subcutaneous (also oral studied) |
| TB-500 (Tβ4) | ~2–2.5 mg | ~2x per week (loading), then weekly | ~4–6 weeks | subcutaneous / intramuscular |
| GHK-Cu | ~1–2 mg, or topical formulations | varies | varies | topical or subcutaneous |
These ranges reflect commonly cited research protocols, not clinical guidelines, and human pharmacokinetics for these peptides are poorly characterized. Dosing should never be improvised. Consult your healthcare provider before starting any peptide protocol.
For peptide-specific detail, see our BPC-157 complete guide, TB-500 complete guide, and GHK-Cu complete guide.
Are these peptides safe to use around surgery?
The honest answer is that safety data in humans — especially around surgery — are limited, and that is itself a reason for caution.
Two specific surgical concerns recur in the literature and in clinical commentary. First, angiogenic and proliferative effects that may help a wound heal could be undesirable in patients with a history of cancer, because the same blood-vessel-forming pathways can theoretically support tumor growth; this is a hypothesized risk, not a documented outcome [VERIFY: oncologic risk is theoretical, not clinically established]. Second, peptides can interact with anesthesia, anticoagulation, and other perioperative medications in ways that have not been studied, and surgeons generally ask patients to disclose all supplements and stop non-essential agents before an operation.
When the FDA placed BPC-157 on its Category 2 interim list in 2023, the agency cited a lack of human safety data, potential for immunogenicity (immune reactions), and uncertainty about peptide-related impurities from compounding (FDA, Interim Policy on Compounding Using Bulk Drug Substances). Research-grade peptides sold online are not manufactured to pharmaceutical standards, so purity, dose accuracy, and sterility are real, documented problems in this market.
Anyone considering a peptide before or after surgery should disclose it to their surgical and anesthesia team. Consult your healthcare provider before starting any peptide protocol.
Are wound-healing peptides legal? FDA status in 2026
Legal status is nuanced and changed materially in 2026. None of these peptides is FDA-approved as a drug for wound healing, and Peptides.NYC does not sell them.
In September 2023, the FDA placed BPC-157 (and several other peptides) into Category 2 of its interim 503A bulk-drug-substances list — the "may present significant safety risks" bucket — which effectively discouraged compounding pharmacies from preparing it (FDA, human-drug-compounding guidance).
In April 2026, the landscape shifted. Per reporting on FDA actions, multiple peptides — including BPC-157, TB-500, MOTS-c, GHK-Cu (injectable), and others — were removed from the interim Category 2 list after nominations were withdrawn and the substances entered a fresh 503A review cycle [VERIFY: exact April 2026 removal date and full peptide list]. The FDA then published a Federal Register notice (FR Doc. 2026-07361, published April 16, 2026; docket FDA-2025-N-6895) scheduling a Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026 to evaluate whether seven bulk substances — including BPC-157, KPV, TB-500, and MOTS-c — should be added to the Section 503A Bulks List. Written public comments are open through July 9, 2026.
Separately, "research use only" (RUO) products exist in a different legal framework from compounding; none of these peptides is a controlled substance under the federal Controlled Substances Act, but RUO material is explicitly not intended for human use. Legal status varies by jurisdiction; consult a lawyer for binding advice. For the current picture, see our peptide legal status 2026 overview.
Where can you learn more or find a practitioner in NYC?
Because access and safety hinge on working with a qualified, licensed provider rather than self-sourcing, the most responsible next step is a conversation with a clinician who understands peptide pharmacology and your medical history — particularly any cancer history, bleeding risk, or upcoming surgery.
Peptides.NYC maintains educational guides on individual peptides and a directory to help you find verified peptide-literate practitioners in NYC. We do not sell peptides and do not provide medical advice.
Frequently asked questions
Q: What is the best peptide for wound healing? A: There is no single "best" peptide for wound healing, and no peptide is FDA-approved for this use. The honest answer depends on the tissue involved, and the comparison rests almost entirely on animal data. In preclinical research, BPC-157 has the most data for tendon, ligament, and muscle repair, where rodent studies report improved biomechanical strength and collagen organization. Thymosin beta-4 / TB-500 is best studied for dermal (skin) wounds and angiogenesis, with a foundational rat study describing faster re-epithelialization. GHK-Cu is best studied for skin regeneration and collagen, elastin, and glycosaminoglycan synthesis. Human clinical evidence is limited for all three, no head-to-head human trials exist, and none should be used without guidance from a healthcare provider who knows your medical history. Consult your healthcare provider before starting any peptide protocol.
Q: Do peptides actually help surgical recovery in humans? A: The honest answer is that this has not been proven in people. The supportive evidence comes mostly from animal models and laboratory studies showing effects on angiogenesis, collagen synthesis, and cell migration — the biological steps involved in tissue repair. Those preclinical signals are genuinely interesting, but "studied in animal models" is not the same as "proven in humans." There are no completed randomized controlled trials demonstrating that BPC-157, TB-500, or GHK-Cu improves surgical outcomes in people, and the most-cited human reports are small, uncontrolled case series. Safety around surgery is also poorly characterized, including possible interactions with anesthesia and anticoagulation. For these reasons, always disclose any peptide use to your surgical and anesthesia team before an operation, and discuss realistic expectations. Consult your healthcare provider before starting any peptide protocol.
Q: How long do healing peptides take to work? A: There is no established human timeline, because no controlled human trials have measured one. In animal studies and uncontrolled case reports, soft-tissue effects are sometimes described over roughly 2–6 weeks, while connective tissue such as tendon and ligament generally takes longer to remodel because it is less vascular and slower to repair. It is important to understand that these timelines come from preclinical or anecdotal sources rather than controlled human research, so they should be read as rough impressions, not promises. Individual response varies with the injury, the tissue, overall health, and many factors that have not been studied in this context. Anyone hoping a peptide will deliver healing on a fixed schedule should temper that expectation and discuss realistic timeframes with a healthcare provider. Consult your healthcare provider before starting any peptide protocol.
Q: Is BPC-157 legal in 2026? A: Legal status is nuanced and changed materially in 2026. BPC-157 is not a federally controlled substance under the Controlled Substances Act, and it is not FDA-approved as a drug for any use. It was placed in Category 2 of the FDA's interim 503A bulk-drug-substances list in September 2023, then removed from that interim list in April 2026 after nominations were withdrawn and the substance entered a fresh 503A review cycle. A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 is scheduled to review whether BPC-157 and several other peptides should be added to the Section 503A compounding list, with written public comments open through July 9, 2026. Separately, "research use only" products exist in a different legal framework and are explicitly not intended for human use. Legal status varies by state; consult a lawyer for binding advice.
Q: Can you take BPC-157 and TB-500 together? A: Some clinic protocols and online sources describe combining BPC-157 and TB-500 for tissue repair, on the rationale that the two act on complementary pathways — BPC-157 is studied mainly in tendon, ligament, and muscle models, while thymosin beta-4 / TB-500 is better characterized in dermal wound and angiogenesis models. That theoretical rationale is not the same as evidence. There are no controlled human studies evaluating the safety or efficacy of this specific combination, so any added benefit is unproven and the combined risk profile is unknown, including how the two might interact with each other or with other medications. Stacking research peptides also multiplies the purity, dosing-accuracy, and sterility concerns that already affect each one individually. Combining research peptides should only be considered, if at all, under the direct supervision of a healthcare provider. Consult your healthcare provider before starting any peptide protocol.
Q: Are there safety risks with wound-healing peptides? A: Yes, and the limited safety data are themselves a reason for caution. Human safety information is sparse for BPC-157, TB-500, and GHK-Cu, and when the FDA placed BPC-157 on its Category 2 interim list it cited a lack of human safety data, the potential for immunogenicity (unwanted immune reactions), and uncertainty about peptide-related impurities from compounding. The angiogenic and proliferative effects that may help a wound close also raise a theoretical concern for people with a history of cancer, because the same blood-vessel-forming pathways can in principle support tumor growth; this is hypothesized, not documented. Because research-grade peptides sold online are not manufactured to pharmaceutical purity standards, contamination, inaccurate dosing, and sterility problems are real and recurring issues in this market. Disclose any peptide use to your provider, especially before surgery. Consult your healthcare provider before starting any peptide protocol.
Q: Does GHK-Cu work for wound healing if applied topically? A: GHK-Cu is widely used in topical skincare, and the strongest human data for it sit in cosmetic dermatology rather than wound care. Human studies report that topical GHK-Cu can improve skin firmness, density, and the appearance of fine lines over roughly 12 weeks. In animal research, GHK-Cu has also been associated with faster wound closure, increased collagen and blood-vessel formation, and antioxidant activity through its binding of copper ions. The important caveat is that topical cosmetic results in healthy skin are not the same as a proven benefit for surgical incisions or deep-tissue wounds, which involve different biology and far higher stakes. Marketing often blurs that line, so claims should be interpreted cautiously and discussed with a clinician rather than taken at face value. Consult your healthcare provider before starting any peptide protocol.
References
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006 May;24(5):982-9. PMID: 16583442. https://pubmed.ncbi.nlm.nih.gov/16583442/
- Chang CH, Tsai WC, Hsu YH, Pang JS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77 (related mechanistic work; growth-hormone-receptor upregulation). PMID: 25415472. https://pubmed.ncbi.nlm.nih.gov/25415472/
- Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999 Sep;113(3):364-8. PMID: 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
- U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and
- U.S. Food and Drug Administration / Office of the Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. FR Doc. 2026-07361; published April 16, 2026; docket FDA-2025-N-6895. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.